MedCity News February 6, 2025
Frank Vinluan

Currently available therapies for Hunter syndrome don’t cross the blood-brain barrier to address cognitive symptoms of the inherited enzyme deficiency. Denali Therapeutics’ technology gets its drug across the protective membrane, and the biotech plans to seek accelerated FDA approval in this rare disease.

A Denali Therapeutics drug for the rare enzyme deficiency Hunter syndrome is still in pivotal testing, but the company has guidance from the FDA on a pathway to get this therapy to the market sooner. Denali now has additional data from an earlier study that will be the main component of an application seeking accelerated approval.

The updated Phase 1/2 data, presented Thursday during the WORLDSymposium conference in San Diego, continue to show benefit for patients, some...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Kroger partners with Express Scripts to expand pharmacy services
Vertex challenger Sionna prices $191M IPO
Some of the Biggest Healthcare Stories from 2024 Involved Pharmacy. What’s Next in 2025?
Insights from JP Morgan 2025: Key trends shaping the pharma industry
“Precision Med Has Evolved as Badly As I Expected” And Other Takeaways From Former FDA Commissioner At PMWC

Share This Article